Bio-Thera Solutions Ltd (688177.SS) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · China · ISIN CNE100003R98
Bio-Thera Solutions Ltd financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 743.17 m CNY | 935.22 m CNY |
| Gross profit | 513.62 m CNY | 738.00 m CNY |
| Operating income | -496.02 m CNY | -346.27 m CNY |
| EBIT | -489.75 m CNY | -311.58 m CNY |
| Net income | -510.30 m CNY | -331.94 m CNY |
| Diluted EPS – continuing operations | -1.23 CNY | -0.80 CNY |
Full history since 2016, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Bio-Thera Solutions Ltd
Bio-Thera Solutions, Ltd., a biopharmaceutical company, researches and develops novel therapeutics for the treatment of cancer, autoimmune, cardiovascular, eye diseases, and other severe unmet medical needs in China and internationally. It offers QLETLI for the treatment of ankylosing spondylitis, rheumatoid arthritis, psoriasis, Crohn's disease, and uveitis; POBEVCY to treat patients with metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, cervical cancer, and epithelial ovarian, fallopian tube, or primary peritoneal cancer; TOFIDENCE for the treatment of rheumatoid arthritis, polyarticular and systemic juvenile idiopathic arthritis, and cytokine release syndrome; and BETAGRIN for the treatment of acute coronary syndromes. The company also develops BAT2206, a biosimilar drug candidate used to treat psoriasis, Crohn's disease, and ulcerative colitis; BAT2306 to treat plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis; and BAT4406F, BAT6026, BAT2606, and BAT2506 for treatment of various autoimmune diseases. In addition, it develops BAT4306F, BAT1308, BAT1006, BAT4706, BAT6026, BAT7104, BAT7104, BAT8006, BAT8010, BAT8008, and BAT8007 for treatment of oncology; BAT2094 and BAT6024 to treat cardiovascular diseases; and BAT5906 that is in Phase III clinical trial for the treatment for wet age-related macular degeneration and diabetic macular edema (DME). The company has a bios imilars alliance with STADA Arzneimittel AG to cover tocilizumab, an immunosuppressant monoclonal antibody indicated for certain inflammatory conditions. The company collaborates with Avalon Pharmaceuticals on BAT2406, a biosimilar of dupixent (dupilumab) across Saudi Arabia and other Middle Eastern, and North African markets. Bio-Thera Solutions, Ltd. was founded in 2003 and is headquartered in Guangzhou, China.
More stocks
- Zhejiang Sanwei Rubber Item Co (603033.SS)
- HARROW, INC. (HROW)
- Renta 4 Banco SA (R4.MC)
- KFORCE INC (KFRC)
- Fugro NV (FUR.AS)
- Ceribell, Inc. (CBLL)
- Power HF Co Ltd (605100.SS)
- Three Squirrels (300783.SZ)
- PT Daya Intiguna Yasa Tbk (MDIY.JK)
- ShenZhen Kondarl Group Co Ltd (000048.SZ)
- Maschinenfabrik Berthold Hermle (MBH3.F)
- Sinar Mas Agro Resources and Technology Tbk PT (SMAR.JK)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.